Please find below a research opportunity for people with confirmed stargardt disease.
News
The latest news from Retina UK. Please use the filters to find the articles which interest you.
Ocugen’s gene therapy candidate, OCU410ST, is an experimental treatment designed to slow vision loss in Stargardt disease, an inherited retinal disease (IRD) with no approved therapies currently.
SpliceBio has begun the dose-expansion portion of their phase 1/2 clinical trial of SB-007, a dual adeno-associated viral vector gene therapy for Stargardt disease.
Opus Genetics has launched an early-stage clinical trial of OPGx-MERTK, an investigational gene therapy for MERTK-related Retinitis Pigmentosa (RP), a condition that causes progressive vision loss due to photoreceptor degeneration.
RP Awareness Month – Paul’s Story
During RP awareness month, Paul Bacon has shared how his diagnosis has impacted his life and shared messages about how non visually impaired people can support those living with inherited sight loss. To learn more about inherited sight loss please take the time to read Paul's story.
People living with sight loss in Scotland are able to benefit from free ferry travel for their companion when travelling with Caledonian MacBrayne (CalMac) Ferries with the NEC+1 card. The ferries operate across Scotland’s islands.
The latest research news piece from Retina UK.
The latest research news from Retina UK.
The latest research news piece from Retina UK.